{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:45:36Z","timestamp":1790109936797,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The specific underlying pathogenesis of prolactinoma has not been clarified yet, to the best of our knowledge. p38 mitogen-activated protein kinase (MAPK) signaling including p38\u03b1 MAPK (MAPK14), p38\u03b2 (MAPK11), p38\u03b3 (MAPK12) and p38\u03b4 (MAPK13) is associated with the development and progression of several types of cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Immunofluorescence analysis was performed on the prolactin (PRL) and MAPK14 expressions of pituitary gland in C57BL\/6 mice and human prolactinoma specimen. In the present study, the role of MAPK14 in prolactinoma was determined using estradiol-induced mice and dopamine D2 receptor knockout (DRD2\n                      <jats:sup>\n                        <jats:bold>\u2212\/\u2212<\/jats:bold>\n                      <\/jats:sup>\n                      ) mice models in C57BL\/6 wild-type (WT), MAPK14\n                      <jats:sup>\n                        <jats:bold>\u2212\/<\/jats:bold>\n                        \u2212\n                      <\/jats:sup>\n                      and DRD2\n                      <jats:sup>\n                        <jats:bold>\u2212\/\u2212<\/jats:bold>\n                      <\/jats:sup>\n                      MAPK14\n                      <jats:sup>+\/\u2212<\/jats:sup>\n                      mice. GH3 cells were transfected with different sets of MAPK14 small interfering RNA, which to study MAPK14 and PRL expression in GH3 cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Immunofluorescence analysis showed that PRL and MAPK14 expression were colocalized and increased in the pituitary gland of mice and human prolactinoma specimen compared with the control specimen. It was shown that PRL and MAPK14 expression was colocalized and increased significantly in the pituitary gland of estradiol-injected prolactinoma mice compared with the control mice. Knockout of MAPK14 significantly inhibited tumor overgrowth, and PRL expression was decreased in estradiol-induced mice. Furthermore, MAPK14 knockout of DRD2\n                      <jats:sup>\n                        <jats:bold>\u2212\/\u2212<\/jats:bold>\n                      <\/jats:sup>\n                      MAPK14\n                      <jats:sup>+\/\u2212<\/jats:sup>\n                      mice significantly reduced the overgrowth of pituitary gland and PRL production and secretion compared with DRD2\n                      <jats:sup>\n                        <jats:bold>\u2212\/\u2212<\/jats:bold>\n                      <\/jats:sup>\n                      mice. MAPK14 knockout using siRNA inhibited PRL production in GH3 cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results suggest that MAPK14 serves a promoting role in the formation of prolactinoma, and highlights the potential of MAPK14 as a potential therapeutic target in the treatment of prolactinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-020-00619-z","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T08:02:41Z","timestamp":1599465761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Inhibiting MAPK14 showed anti-prolactinoma effect"],"prefix":"10.1186","volume":"20","author":[{"given":"Qiao-yan","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-hu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"issue":"5","key":"619_CR1","first-page":"319","volume":"88","author":"MG Lake","year":"2013","unstructured":"Lake MG, Krook LS, Cruz SV. Pituitary adenomas: an overview. Am Fam Physician. 2013;88(5):319\u201327.","journal-title":"Am Fam Physician"},{"key":"619_CR2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrendo.2011.37","volume":"7","author":"A Colao","year":"2001","unstructured":"Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol. 2001;7:267\u201378.","journal-title":"Nat Rev Endocrinol"},{"key":"619_CR3","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769\u201375.","journal-title":"J Clin Endocrinol Metab"},{"key":"619_CR4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485\u2013534.","journal-title":"Endocr Rev"},{"key":"619_CR5","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","volume":"114","author":"MC Oh","year":"2011","unstructured":"Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. J Neurosurg. 2011;114:1369\u201379.","journal-title":"J Neurosurg"},{"key":"619_CR6","first-page":"1358","volume":"2007","author":"A Cuenda","year":"1773","unstructured":"Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 1773;2007:1358\u201375.","journal-title":"Biochim Biophys Acta"},{"key":"619_CR7","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.cellsig.2009.11.020","volume":"22","author":"G Remy","year":"2010","unstructured":"Remy G, Risco AM, I\u00f1esta-Vaquera FA, Gonz\u00e1lez-Ter\u00e1n B, Sabio G, Davis RJ, Cuenda A. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal. 2010;22:660\u20137.","journal-title":"Cell Signal"},{"key":"619_CR8","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.4049\/jimmunol.180.7.5075","volume":"180","author":"YJ Kang","year":"2008","unstructured":"Kang YJ, Chen J, Otsuka M, Mols J, Ren S, Wang Y, Han J. Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J Immunol. 2008;180:5075\u201382.","journal-title":"J Immunol"},{"key":"619_CR9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ni.1640","volume":"9","author":"C Kim","year":"2008","unstructured":"Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, Celada A, Lawrence T, Otsu K, Brissette JL, Arthur JS, et al. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates proand anti-inflammatory gene expression. Nat Immunol. 2008;9:1019\u201327.","journal-title":"Nat Immunol"},{"key":"619_CR10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1053\/j.gastro.2010.01.005","volume":"138","author":"M Otsuka","year":"2010","unstructured":"Otsuka M, Kang YJ, Ren J, Jiang H, Wang Y, Omata M, Han J. Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology. 2010;138:1255\u201365.","journal-title":"Gastroenterology"},{"key":"619_CR11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/gast.2002.30770","volume":"122","author":"D Hommes","year":"2002","unstructured":"Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 2002;122:7\u201314.","journal-title":"Gastroenterology"},{"key":"619_CR12","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1096\/fj.04-1642fje","volume":"18","author":"E Hollenbach","year":"2004","unstructured":"Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK\/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J. 2004;18:1550\u20132.","journal-title":"FASEB J"},{"key":"619_CR13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cgh.2005.11.013","volume":"4","author":"S Schreiber","year":"2006","unstructured":"Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:325\u201334.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"619_CR14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gut.50.4.507","volume":"50","author":"T ten Hove","year":"2002","unstructured":"ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut. 2002;50:507\u201312.","journal-title":"Gut"},{"key":"619_CR15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/15275","volume":"5","author":"AP Heaney","year":"1999","unstructured":"Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med. 1999;5:1317\u2013721.","journal-title":"Nat Med"},{"key":"619_CR16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000094308","volume":"35","author":"C Cristina","year":"2006","unstructured":"Cristina C, Garc\u00eda-Tornad\u00fa I, D\u00edaz-Torga G, Rubinstein M, Low MJ. Bec\u00fa- Villalobos D: dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res. 2006;35:50\u201363.","journal-title":"Front Horm Res"},{"key":"619_CR17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11248-014-9823-y","volume":"23","author":"D Seruggia","year":"2014","unstructured":"Seruggia D. Montoliu L:the new CRISPR-Cas system: RNA-guided genome engineering to efficiently produce any desired genetic alteration in animals. Transgenic Res. 2014;23:707\u201316.","journal-title":"Transgenic Res"},{"key":"619_CR18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0896-6273(00)80351-7","volume":"19","author":"MA Kelly","year":"1997","unstructured":"Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK, et al. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron. 1997;19:103\u201313.","journal-title":"Neuron"},{"key":"619_CR19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394Cq method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"619_CR20","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jocn.2015.03.059","volume":"22","author":"A Wong","year":"2015","unstructured":"Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci. 2015;22:1568\u201374.","journal-title":"J Clin Neurosci"},{"issue":"5","key":"619_CR21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317(5):516\u201324.","journal-title":"JAMA"},{"key":"619_CR22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167:651\u201362.","journal-title":"Eur J Endocrinol"},{"key":"619_CR23","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","volume":"120","author":"M Burotto","year":"2014","unstructured":"Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120:3446\u201356.","journal-title":"Cancer"},{"key":"619_CR24","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1002\/cncr.11425","volume":"97","author":"K Iyoda","year":"2003","unstructured":"Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, Takehara T, Fujimoto J, Hori M, Wands JR, et al. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer. 2003;97:3017\u201326.","journal-title":"Cancer"},{"key":"619_CR25","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1074\/jbc.M204863200","volume":"278","author":"PW Tsai","year":"2003","unstructured":"Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38\/nuclear factor-kappa B signaling pathway. J Biol Chem. 2003;278:5750\u2013959.","journal-title":"J Biol Chem"},{"key":"619_CR26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10585-004-3503-x","volume":"21","author":"C Suarez-Cuervo","year":"2004","unstructured":"Suarez-Cuervo C, Merrell MA, Watson L, Harris KW, Rosenthal EL, V\u00e4\u00e4n\u00e4nen HK, Selander KS. Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis. 2004;21:525\u201333.","journal-title":"Clin Exp Metastasis"},{"key":"619_CR27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1165\/ajrcmb.26.5.4689","volume":"26","author":"AK Greenberg","year":"2002","unstructured":"Greenberg AK, Basu S, Hu J, Yie TA, Tchou-Wong KM, Rom WN, Lee TC. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol. 2002;26:558\u201364.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"619_CR28","first-page":"1557","volume":"34","author":"B Kumar","year":"2009","unstructured":"Kumar B, Sinclair J, Khandrika L, Koul S, Wilson S, Koul HK. Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells. Int J Oncol. 2009;34:1557\u201364.","journal-title":"Int J Oncol"},{"key":"619_CR29","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/0008-5472.CAN-09-2918","volume":"70","author":"B Kumar","year":"2010","unstructured":"Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, Wilson S, Koul HK. p38 mitogenactivated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res. 2010;70:832\u201341.","journal-title":"Cancer Res"},{"key":"619_CR30","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1038\/sj.onc.1206478","volume":"22","author":"JI Park","year":"2003","unstructured":"Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene. 2003;22:4314\u201332.","journal-title":"Oncogene"},{"key":"619_CR31","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/onc.2008.476","volume":"28","author":"L Khandrika","year":"2009","unstructured":"Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, Chandhoke R, Meacham RB, Koul HK. Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene. 2009;28:1248\u201360.","journal-title":"Oncogene"},{"key":"619_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1478-811X-2-5","volume":"2","author":"PD Maroni","year":"2004","unstructured":"Maroni PD, Koul S, Meacham RB, Koul HK. Mitogen activated protein kinase signal transduction pathways in the prostate. Cell Commun Signal. 2004;2:5.","journal-title":"Cell Commun Signal"},{"key":"619_CR33","doi-asserted-by":"crossref","first-page":"21086","DOI":"10.1074\/jbc.M001281200","volume":"275","author":"RY Liu","year":"2000","unstructured":"Liu RY, Fan C, Liu G, Olashaw NE, Zuckerman KS. Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha-supported proliferation of leukemia and lymphoma cell lines. J Biol Chem. 2000;275:21086\u201393.","journal-title":"J Biol Chem"},{"key":"619_CR34","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1073\/pnas.1137463100","volume":"100","author":"KS Elenitoba-Johnson","year":"2003","unstructured":"Elenitoba-Johnson KS, Jenson SD, Abbott RT, Palais RA, Bohling SD, Lin Z, Tripp S, Shami PJ, Wang LY, Coupland RW, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A. 2003;100:7259\u201364.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"619_CR35","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1074\/mcp.M400008-MCP200","volume":"3","author":"Z Lin","year":"2004","unstructured":"Lin Z, Crockett DK, Jenson SD, Lim MS, Elenitoba-Johnson KS. Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol Cell Proteomics. 2004;3:820\u201333.","journal-title":"Mol Cell Proteomics"},{"key":"619_CR36","doi-asserted-by":"crossref","first-page":"14530","DOI":"10.1073\/pnas.222319599","volume":"99","author":"C Iaccarino","year":"2002","unstructured":"Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R, Borrelli E. Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. Proc Natl Acad Sci U S A. 2002;99:14530\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"619_CR37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1124\/pr.107.00106","volume":"60","author":"T Boutros","year":"2008","unstructured":"Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase\/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev. 2008;60(3):261\u2013310.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"619_CR38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","volume":"75","author":"M Cargnello","year":"2011","unstructured":"Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50\u201383.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"10","key":"619_CR39","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/febs.13250","volume":"282","author":"J Gupta","year":"2015","unstructured":"Gupta J, Nebreda AR. Roles of p38\u03b1 mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer. FEBS J. 2015;282(10):1841\u201357.","journal-title":"FEBS J"},{"issue":"5","key":"619_CR40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00109-015-1376-x","volume":"94","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med (Berl). 2016;94(5):509\u201322.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"619_CR41","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523\u2013631.","journal-title":"Physiol Rev"},{"issue":"3","key":"619_CR42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","volume":"19","author":"C Bole-Feysot","year":"1998","unstructured":"Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19(3):225\u201368.","journal-title":"Endocr Rev"},{"issue":"6","key":"619_CR43","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"N Ben-Jonathan","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724\u201363.","journal-title":"Endocr Rev"},{"issue":"2 Suppl","key":"619_CR44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","volume":"22","author":"P Fitzgerald","year":"2008","unstructured":"Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(2 Suppl):12\u20139.","journal-title":"J Psychopharmacol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00619-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-020-00619-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00619-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T19:05:10Z","timestamp":1630955110000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-020-00619-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1186\/s12902-020-00619-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-22129\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22129\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22129\/v2","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"21 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Ethics Committee of Tongren Hospital Affiliated to Wuhan University, The Third Hospital of Wuhan. All samples and data from participants were anonymized and their written informed consent was obtained. The present study was approved by the Institutional Research Ethics Committee of the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology. This study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication NO.85\u201323, revised 1996). All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}